Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
new york blog main
6
×
new york top stories
boston blog main
boston top stories
national top stories
fda
san diego blog main
san diego top stories
biotech
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
drugs
europe blog main
europe top stories
inotersen
national
new york
patisiran
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
rna interference
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
What
fda
6
×
patients
6
×
drug
ago
alnylam
approved
disease
friday
help
medicine
acorda
akcea
amyloidosis
approval
approve
aren’t
attr
available
awaits
battle
bid
bio
biological
boehringer
cancer
cope
crossed
debilitating
decades
decision
developers
diabetes
discovered
drugs
eisai
eli
episodes
expand
fallen
fingers
Language
unset
Current search:
patients
×
fda
×
" new york blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision